Clinical trial · Observational
Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions
Exploratory Study on the Efficacy of 68Ga-Pentixafor PET/MR in Detecting Lesions in Non-Hodgkin Lymphoma and Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma (MM) | Multiple Myeloma | CURATED_EXACT | 0.85 |
| Non Hodgkin's Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Research group
- description
- It is expected to include 30 newly diagnosed NHL or MM patients, and the tracer radiation used in the study is extremely small and will not have any physiological effects on the subjects.
Primary outcomes (2)
- measure
- Ann Arbor staging
- timeFrame
- After the patient signs the informed consent form and completes the scan, an average of 2 days.
- description
- All patients were classified into stages I-IV based on Ann Arbor staging according to visual methods.
- measure
- Metabolic parameters
- timeFrame
- After the patient signs the informed consent form and completes the scan, an average of 2 days.
- description
- Calculate maximum standardized uptake value (SUVmax (lesion)) of all affected lymphoma and extranodal organs. Set a region of interest with a diameter of approximately 10mm in the descending segment of the thoracic aorta, calculate the standardized uptake value (SUVmean) of the mediastinal blood pool, calculate SUVmax (lesion)/SUVmean (blood pool).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age of 18 years or older 2. ECOG \< 2 3. Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination 4. Completion of 18F-FDG PET/CT or PET/MR imaging within the past week in our department Exclusion Criteria: 1. Pregnant and breastfeeding women; 2. Individuals with severe hepatic and renal failure; 3. Patients with concurrent malignancies; 4. Individuals unable to remain supine for a duration of 30 minutes to complete the examination; 5. Patients with diagnosed claustrophobia; 6. Patients containing metallic implants; 7. Individuals deemed unsuitable for participation in clinical trials by researchers.
References
Publications (0)
Data not yet available